Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Queensland Health
AstraZeneca
Cipla
US Department of Justice
Accenture

Generated: March 19, 2019

DrugPatentWatch Database Preview

NAPROXEN SODIUM Drug Profile

« Back to Dashboard

Which patents cover Naproxen Sodium, and what generic alternatives are available?

Naproxen Sodium is a drug marketed by Bionpharma Inc, Puracap Pharm Llc, Actavis Labs Fl Inc, Able, Amneal Pharms Ny, Aurobindo Pharma Ltd, Contract Pharmacal, Dr Reddys Labs Inc, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Granules India, Hamilton Pharms, Hikma, Ivax Sub Teva Pharms, Lnk Intl Inc, Marksans Pharma, Mylan, Novelgenix Theraps, Perrigo, Pld Acquisitions Llc, Pliva, Purepac Pharm, Roxane, Sandoz, Sun Pharm Inds Ltd, Teva, Teva Pharms, Watson Labs, and Amneal Pharms Co. and is included in thirty-seven NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in thirteen countries.

The generic ingredient in NAPROXEN SODIUM is naproxen sodium; pseudoephedrine hydrochloride. There are forty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the naproxen sodium; pseudoephedrine hydrochloride profile page.

Drug patent expirations by year for NAPROXEN SODIUM
Pharmacology for NAPROXEN SODIUM
Synonyms for NAPROXEN SODIUM
(-)-Naproxen sodium
(-)-Sodium (S)-6-methoxy-alpha-methyl-2-naphthaleneacetate
(2S)-2-(6-Methoxy-2-naphthyl)propanoic acid sodium salt
(2s)-2-(6-methoxy(2-naphthyl))propanoic acid sodium salt
(S)-6-Methoxy-|A-methyl-2-naphthaleneacetic acid sodium salt
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium salt
(S)-Naproxen Sodium Salt
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, sodium salt, (S)-
2-NAPHTHALENEACETIC ACID, 6-METHOXY-alpha-METHYL-, SODIUM SALT, L-(-)-
26159-34-2
59N342
9TN87S3A3C
A-Nox
A818221
AB0013373
AB2000172
AC1Q1V3H
AKOS015895696
AKOS015994759
Aleve
Anapran
Anaprotab
Anaprox
Anaprox (TN)
ANAPROX DS
API0003516
Apo-Napro-NA
Aprol
Aprowell
Axer Alfa
BAY H6689
BAYH6689
BCP0726000300
BCP9000977
BIM-0050769.0001
C-15574
C14H13NaO3
C14H13O3.Na
CAS-26159-34-2
Causalon Pro
CC-32459
CCG-101082
CDBRNDSHEYLDJV-FVGYRXGTSA-M
CHEBI:7477
CHEMBL1200806
CPD000058746
CS-2162
CTK8G1633
D00970
Diocodal
DSSTox_CID_25576
DSSTox_GSID_45576
DSSTox_RID_80973
DTXSID7045576
Dysmenalgit
EINECS 247-486-2
EU-0100792
Flanax
Flogen
Floginex
Flogogin
Floneks
Floxalin
FT-0630524
Gibinap
Gibixen
H939
HMS1570O04
HMS2052G05
HMS2230D08
HMS3262O06
HMS3269J19
HY-15030A
J10445
Kapnax
Karoksen
KS-00000XJS
KS-5141
L-(-)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid sodium salt
Laser
Leniartril
Lopac-M-1275
LP00792
LS-94350
M 1275
MFCD00058507
Miranax
MLS000069555
MLS001076076
MLS001424214
MolPort-003-849-327
Monarit
Naprelan
Naprium
Naprodil
Naprodol
Naprovite
Naproxen (Aleve)
Naproxen (sodium)
Naproxen natrium
Naproxen sodium (USP)
Naproxen sodium [USAN:USP]
Naproxen sodium [USAN]
Naproxen sodium salt
Naproxen sodium, 98.0-102.0%
Naproxen sodium, 98%
Naproxen sodium, meets USP testing specifications
Naproxen sodium, Pharmaceutical Secondary Standard; Certified Reference Material
Naproxen sodium, United States Pharmacopeia (USP) Reference Standard
Naproxen Sodium,(S)
Naprux
Naprux Gesic
Natrioxen
NC00332
NCGC00016166-01
NCGC00016759-04
NCGC00017097-01
NCGC00017097-02
NCGC00094127-01
NCGC00261477-01
Nixal
Opera_ID_1200
Opraks
Pactens
Prexan
Primeral
Proxen
PubChem19878
RS 3650
RS-3650
S1626
SAM001246874
SCHEMBL7361
SMR000058746
Sodimax
Sodium (-)-2-(6-methoxy-2-naphthyl)propionate
sodium (2S)-2-(6-methoxy-2-naphthalenyl)propanoate
sodium (2S)-2-(6-methoxy-2-naphthyl)propanoate
sodium (2S)-2-(6-methoxynaphthalen-2-yl)propanoate
sodium (S)-2-(6-methoxy-2-naphthyl)propionate
sodium (S)-2-(6-methoxynaphthalen-2-yl)propanoate
sodium naproxen
sodium;(2S)-2-(6-methoxynaphthalen-2-yl)propanoate
Sunprox
SW197105-3
Synflex
Tandax
Topcare all day pain relief
Tox21_110774
Tox21_110774_1
Tox21_500792
UNII-9TN87S3A3C
UNM-0000306098
VA11355
Veradol
W-107195
Xenar

US Patents and Regulatory Information for NAPROXEN SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pliva NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074242-002 Jun 20, 1996 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ivax Sub Teva Pharms NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074230-002 Mar 14, 1995 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sandoz NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074495-002 Dec 5, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074455-002 May 31, 1995 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Roxane NAPROXEN SODIUM naproxen sodium TABLET;ORAL 074257-002 Dec 21, 1993 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharm Inds Ltd NAPROXEN SODIUM naproxen sodium TABLET;ORAL 091183-001 May 20, 2011 OTC No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM
Drugname Dosage Strength RLD Date
➤ Subscribe Capsules 200 mg ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for NAPROXEN SODIUM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1411900 122012000052 Germany ➤ Sign Up PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
1411900 2011/016 Ireland ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0984957 SPC/GB11/013 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900 1190013-1 Sweden ➤ Sign Up PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900 SPC/GB11/015 United Kingdom ➤ Sign Up PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0984957 PA2011005 Lithuania ➤ Sign Up PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
US Department of Justice
QuintilesIMS
Teva
Argus Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.